Corticosteroid-modulated Immune Activation in the Tuberculosis Immune Reconstitution Inflammatory Syndrome

被引:66
|
作者
Meintjes, Graeme [1 ,4 ,5 ]
Skolimowska, Keira H.
Wilkinson, Katalin A. [6 ]
Matthews, Kerryn
Tadokera, Rebecca
Conesa-Botella, Anali [7 ,8 ]
Seldon, Ronnett
Rangaka, Molebogeng X.
Rebe, Kevin [4 ]
Pepper, Dominique J.
Morroni, Chelsea [2 ]
Colebunders, Robert [7 ,8 ]
Maartens, Gary [3 ]
Wilkinson, Robert J. [4 ,5 ,6 ]
机构
[1] Univ Cape Town, Fac Hlth Sci, Inst Infect Dis & Mol Med, Clin Infect Dis Res Initiat, ZA-7925 Cape Town, South Africa
[2] Univ Cape Town, Sch Publ Hlth & Family Med, Womens Hlth Res Unit, ZA-7925 Cape Town, South Africa
[3] Univ Cape Town, Dept Med, Div Clin Pharmacol, ZA-7925 Cape Town, South Africa
[4] GF Jooste Hosp, Cape Town, South Africa
[5] Univ London Imperial Coll Sci Technol & Med, Dept Med, London, England
[6] Natl Inst Med Res, London NW7 1AA, England
[7] Univ Antwerp, Inst Trop Med, Dept Clin Sci, B-2020 Antwerp, Belgium
[8] Univ Antwerp, Dept Epidemiol & Social Med, B-2020 Antwerp, Belgium
基金
英国惠康基金; 英国医学研究理事会;
关键词
human immunodeficiency virus; tuberculosis; immune reconstitution; inflammatory syndrome; glucocorticoids; HIV-INFECTED ADULTS; MYCOBACTERIUM-TUBERCULOSIS; T-CELLS; ANTIRETROVIRAL THERAPY; CASE DEFINITIONS; CLINICAL-TRIAL; DISEASE; PREDNISOLONE; MENINGITIS; DEXAMETHASONE;
D O I
10.1164/rccm.201201-0094OC
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Rationale: HIV-tuberculosis-associated immune reconstitution inflammatory syndrome (TB-IRIS) is an immunopathological reaction to mycobacterial antigens induced by antiretroviral therapy. Prednisone reduces morbidity in TB-IRIS, but the mechanisms are unclear. Objectives: To determine the effect of prednisone on the inflammatory response in TB-IRIS (antigen-specific effector T cells, cytokines, and chemokines). Methods: Blood was taken from participants in a randomized placebo-controlled trial of prednisone for TB-IRIS, at 0, 2, and 4 weeks. Participants received prednisone at a dosage of 1.5 mg/kg/day for 2 weeks followed by 0.75 mg/kg/day for 2 weeks, or placebo at identical dosages. Measurements and Main Results: Analyses included IFN-gamma enzyme-linked immunospot (ELISPOT), reverse transcription-polymerase chain reaction on peripheral blood mononuclear cells after restimulation with heat-killed Mycobacterium tuberculosis, Luminex multiplex cytokine analysis of corresponding tissue culture supernatants, and Luminex multiplex cytokine analysis of serum. Fifty-eight participants with TB-IRIS (31 receiving prednisone, 27 receiving placebo) were included. In serum, significant decreases in IL-6, IL-10, IL-12 p40, tumor necrosis factor-alpha, IFN-gamma, and IFN-gamma-induced protein-10 concentrations during prednisone, but not placebo, treatment were observed. No differences in ELISPOT responses comparing prednisone and placebo groups were shown in response to ESAT-6 (early secreted antigen target-6), Acr1, Acr2, 38-kD antigen, or heat-killed H37Rv M. tuberculosis. Purified protein derivative ELISPOT responses increased over 4 weeks in the prednisone group and decreased in the placebo group (P = 0.007). Conclusions: The beneficial effects of prednisone in TB-IRIS appear to be mediated via suppression of predominantly proinflammatory cytokine responses of innate immune origin, not via a reduction of the numbers of antigen-specific T cells in peripheral blood.
引用
收藏
页码:369 / 377
页数:9
相关论文
共 50 条
  • [42] Immune reconstitution inflammatory syndrome in leprosy
    Huber, Milo
    Bertischl, Barbara
    Boeddinghaus, Boris
    Peter, Silke
    Guenthard, Huldrych
    Weber, Rainer
    Beck, Bernhard
    SWISS MEDICAL WEEKLY, 2007, 137 : 50S - 50S
  • [43] Leprosy in immune reconstitution inflammatory syndrome
    Teo, Y.
    Walker, S.
    Lockwood, D.
    Giles, A.
    Hoque, S.
    Banerjee, P.
    BRITISH JOURNAL OF DERMATOLOGY, 2018, 179 : 147 - 147
  • [44] Immune reconstitution inflammatory syndrome DISCUSSION
    Godeau, M. Pierre
    Binet, M. Jacques-Louis
    BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2011, 195 (03): : 575 - 575
  • [45] Cryptococcal immune reconstitution inflammatory syndrome
    Longley, Nicky
    Harrison, Thomas S.
    Jarvis, Joseph N.
    CURRENT OPINION IN INFECTIOUS DISEASES, 2013, 26 (01) : 26 - 34
  • [46] Sarcoid Immune Reconstitution Inflammatory Syndrome
    Byrne, J.
    Brennan, S.
    McMenamin, M.
    Bergin, C.
    HIV MEDICINE, 2021, 22 : 307 - 308
  • [47] Immune reconstitution inflammatory syndrome (IRIS)
    Wagner, A. D.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2008, 67 (04): : 284 - +
  • [48] Immune reconstitution inflammatory syndrome in HIV
    Lipman, M
    Breen, R
    CURRENT OPINION IN INFECTIOUS DISEASES, 2006, 19 (01) : 20 - 25
  • [49] Infliximab use for corticosteroid-resistant tuberculosis immune reconstitution inflammatory syndrome (TB-IRIS) in an immunocompetent patient
    Eshagh, Deborah
    Benali, Khadija
    Dossier, Antoine
    Chauveheid, Marie Paule
    Rouzaud, Diane
    Goulenok, Tiphaine
    Papo, Thomas
    Sacre, Karim
    INFECTION, 2020, 48 (05) : 799 - 802
  • [50] Immune reconstitution inflammatory syndrome (IRIS syndrome)
    Sereni, D.
    Bourgarit, A.
    REVUE DE MEDECINE INTERNE, 2009, 30 : S15 - S16